<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895205</url>
  </required_header>
  <id_info>
    <org_study_id>PP-02</org_study_id>
    <nct_id>NCT01895205</nct_id>
  </id_info>
  <brief_title>Treatment of Women After Severe Postpartum Haemorrhage</brief_title>
  <acronym>PP-02</acronym>
  <official_title>A Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Red Blood Cell Transfusion in Women With Severe Postpartum Iron Deficiency Anaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioStata</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to get explorative information about IV high single dose&#xD;
      infusion of iron isomaltoside 1000 compared to RBC transfusion in the treatment of severe&#xD;
      PP-IDA evaluated as physical fatigue&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Fatigue</measure>
    <time_frame>From exposure to 12 weeks post-exposure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hb concentration</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in p-ferritin</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue symptoms</measure>
    <time_frame>from baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum depression</measure>
    <time_frame>From week 1 to 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding</measure>
    <time_frame>From exposure to 12 weeks post-exposure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse drug reactions (ADRs)</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in p-iron</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in p-transferrin</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in transferrin saturation (TSAT)</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in reticulocyte count</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change mean reticulocyte haemoglobin content (CHr)</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in anaemia symptoms</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in gastrointestinal symptoms</measure>
    <time_frame>From Baseline to week 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Severe Postpartum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Iron isomaltoside 1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red blood cell transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allogenic RBC transfusion is dosed to trigger Hb:&#xD;
Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC&#xD;
Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron isomaltoside 1000</intervention_name>
    <arm_group_label>Iron isomaltoside 1000</arm_group_label>
    <other_name>Monofer®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Red blood cell transfusion</intervention_name>
    <arm_group_label>Red blood cell transfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. PPH &gt; 1000 mL&#xD;
&#xD;
          2. Hb ≥ 5.5 and ≤ 8.0 g/dL (≥ 3.5 and ≤ 5.0 mmol/L)&#xD;
&#xD;
          3. Willingness to participate and signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women aged &lt; 18 years&#xD;
&#xD;
          2. Multiple births&#xD;
&#xD;
          3. Peripartum RBC transfusion&#xD;
&#xD;
          4. Known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and&#xD;
             haemosiderosis)&#xD;
&#xD;
          5. Known hypersensitivity to parenteral iron or any excipients in the investigational&#xD;
             drug products&#xD;
&#xD;
          6. Women with a history of active asthma within the last 5 years or a history of multiple&#xD;
             allergies&#xD;
&#xD;
          7. Known decompensated liver cirrhosis and active hepatitis&#xD;
&#xD;
          8. Women with HELLP (Haemolysis Elevated Liver enzymes Low Platelet count) syndrome&#xD;
             (defined according to &quot;Dansk Selskab for Obstetrik og Gynækologi guidelines&quot;)&#xD;
&#xD;
          9. Active acute infection assessed by clinical judgement&#xD;
&#xD;
         10. Rheumatoid arthritis with symptoms or signs of active joint inflammation&#xD;
&#xD;
         11. History of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia&#xD;
             (known haematologic disorder other than iron deficiency)&#xD;
&#xD;
         12. Not able to read, speak and understand the Danish language&#xD;
&#xD;
         13. Participation in any other clinical study where the study drug has not passed 5&#xD;
             half-lives prior to the baseline&#xD;
&#xD;
         14. Any other medical condition that, in the opinion of Investigator, may cause the&#xD;
             patient to be unsuitable for completion of the study or place the patient at potential&#xD;
             risk from being in the study. For example, a malignancy, uncontrolled hypertension,&#xD;
             unstable ischaemic heart disease or uncontrolled diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>July 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron isomaltoside 1000</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

